Victory Capital Holdings heads into its Q1 earnings call — scheduled for May 7 — having climbed nearly 30% over the past month to $81.26. The Street's average price target of $74.80 is now trailing the stock price. That gap is the central tension of the week.
Options traders have moved sharply bullish, and that shift is striking. The put/call ratio has collapsed to 0.21, less than half its 20-day average of 0.44. The reading represents a near-complete reversal from the hedged posture that prevailed through March and early April, when the PCR was running around 0.76–0.90. Calls now dominate the options book by a wide margin — a clear signal that participants have been positioning for continued upside rather than protecting against a pullback.
The short book doesn't contradict that enthusiasm. Short interest is modest at 4.7% of free float, and the lending market is loose — borrow availability is ample, cost to borrow is just 0.50%, and the ORTEX short score of 51.3 is near the middle of the range. Short sellers trimmed by around 4% on May 5 alone. The combination of falling short interest, minimal borrow cost, and a PCR near its 52-week low suggests no meaningful squeeze dynamic and no organised bearish conviction. Positioning looks constructive rather than contested.
The analyst community has been slower to follow the price. Consensus sits at a hold, with four analysts on record and a mean target of $74.80 — roughly 8% below where the stock closed Tuesday. JP Morgan raised its target to $72 in late April, and Barclays lifted to $74 at the same time. Both maintained neutral-equivalent ratings. RBC Capital remains the most constructive name, carrying an Outperform with an $84 target from February. The stock has now traded through that target too. Valuation has re-rated meaningfully with the move: the P/E multiple has expanded by roughly 2.6 turns over the past month to around 11.5x, and EV/EBITDA has risen to 7.8x. Neither multiple looks stretched for an asset manager of this size, but the stock is no longer cheap relative to where analysts have been modelling it.
The insider picture is worth noting. A cluster of executives — CEO David Brown, CFO Michael Policarpo, CLO Nina Gupta, and division President Mannik Dhillon — all sold shares on March 13, at prices around $66.67. Brown sold 50,457 shares for roughly $3.4 million. The timing is relevant: those sales came roughly six weeks before the stock's sharp move higher. The 90-day net insider position works out to a net sale of around $6.9 million in value. That said, the annual pattern is consistent — the same executives sold in March 2025 and March 2024 as well, which suggests a routine compensation-related cycle rather than a directional signal. Institutionally, BlackRock added around 70,000 shares as of April 30, and Capital Research added 155,000 shares in Q1 — both modest but incrementally positive signals.
Among peers, the contrast this week is notable. Blue Owl Capital gained 14.7% on the week and Ares Management was broadly flat — two alternatives-focused names that, like VCTR, benefited from the market's improved risk appetite. In contrast, advisory-heavy names including Perella Weinberg and Moelis dropped sharply, each down 15–18%. That divergence underlines how the rally in VCTR is tied to asset-management sentiment rather than broader financial services. What to watch at the earnings call: whether AUM flows and fee rate trends justify a price that has now moved well past every published analyst target.
See the live data behind this article on ORTEX.
Open VCTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
